Crizanlizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Crizanlizumab
Monoclonal antibody
Type ?
Source Humanized
Target selectin P
Clinical data
ATC code
  • none
Identifiers
ChemSpider
  • none

Crizanlizumab is a monoclonal antibody developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with Sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.[1]

Pathophysiology[edit]

P-selectin molecules are present on the surface of vascular endothelial cells and have been linked to Sickle cell vaso-occlusive crises.[2]

References[edit]

  1. ^ "Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease". New England Journal Medicine. Retrieved 5 December 2016. 
  2. ^ "Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies" (122(24)). 2013: 3892–3898.